Comparison of Post Operative Analgesia in Patients Undergoing Lower Abdominal Surgeries Receiving Ultrasound Guided Block With Dexmetomidine vs Dexmethasone

March 27, 2026 updated by: Department of Anesthesia, Pakistan Institute of Medical Sciences

Comparison of Mean Duration of Post Operative Analgesia in Patients Undergoing Lower Abdominal Surgeries Receiving US Transversus Abdominis Plane Block (TAP) With Bupivacaine and Dexmetomidine vs Bupivacaine nd Dexmethasone

Lower abdominal surgeries cause significant pain and can be managed by injecting local anesthetic agents between muscles of abdominal wall that can provide post operative pain relief and its duration can be prolonged by adding drugs to local anesthetic regimen

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

TAPP block can provide significant post operative analgesia following lower abdominal surgery and its duration can be prolonged by adding adjuvants to local anesthetics.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Pakistan
    • Federal
      • Islamabad, Federal, Pakistan, 44000
        • Recruiting
        • Pakistan Institute of Medical Sciences Islamabad
        • Contact:
          • Naheed Fatima Head of Department, MBBS,FCPS
          • Phone Number: +92-300-5236655
          • Email: naheedfk73@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • ASA I and ASA II BMI 25-35 kg/m2 Lower abdominal surgeries below L2-L3 leves

Exclusion Criteria:

  • Infection at block site Coagulopathy Antiplatelet

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Dexamethasone
Drug: Dexamethasone
20 ml 0.25% Bupivacaine along with 4 mg of Dexamethasone will be given in TAPP block bilaterally
Active Comparator: Dexmedetomidine
Drug: Dexmedetomidine
20 ml 0.25% Bupivacaine along with 0.5 Mcg/kg of Dexmedetomidine will be given in TAPP block bilaterally

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Resuce analgesia
Time Frame: Time in the post operative period when patient first demands rescues analgesia will be noted in minutes
Time in the post operative period when patient first demands rescues analgesia will be noted in minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pakistan Institute of Medical Sciences

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Sobhy YS, Gadalla RR, Nofal WH, Saleh MAE, Abdou KM. A comparative study between the use of dexmedetomidine .vs dexamethasone as adjuvants to bupivacaine in ultrasound-guided transversus abdominis plane block for postoperative pain relief in patients undergoing lower abdominal surgeries. Anaesth. pain intensive care 2022;26(5):681-688

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 27, 2026

Primary Completion (Estimated)

June 26, 2026

Study Completion (Estimated)

June 26, 2026

Study Registration Dates

First Submitted

March 27, 2026

First Submitted That Met QC Criteria

March 27, 2026

First Posted (Actual)

April 2, 2026

Study Record Updates

Last Update Posted (Actual)

April 2, 2026

Last Update Submitted That Met QC Criteria

March 27, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • F52/2024(ERRC)/PIMS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Hospital Ethical Committe doesnt allow

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dexmedetomidine

Clinical Trials on Dexmedetomidine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe